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Research ethics challenges during the COVID-19 pandemic: what 
should and what should not be done 




This article is directed primarily at how clinical trials can be ethically conducted in the midst of the current global COVID-
19 pandemic. We explain why ethical issues are more complicated than they once were. Furthermore, we discuss the 
relevant parties` roles in protecting participants` rights and keeping basic research ethics of justice, respect, equity, and 
beneficence strongly implemented.   
 
 Keywords:  COVID-19 pandemic, Ethic committee approval, Article, Saudi Arabia 
 
Background  
In the time of COVID-19, where coronavirus disease has spread 
across the globe infecting the four corners of the Earth, research 
centers and major laboratories are frantically racing to come 
forward with a medicinal formula that kills the virus and ends 
the hardship. Aside from the disease being phenomenally 
contagious, to date, it has no treatment. 
     The COVID-19 crisis has emerged first as a health issue and 
shortly branched around to affect the economy and politics 
strongly. Moreover, it ruined societies at large, leaving no social 
life to speak of. As a result of the political conflict as to why 
and where the pandemic has stemmed from, the global powers 
came up to heated arguments where every part is determined to 
win the battle whatever it costs. Amid the unprecedented 
international storm, research bioethics loom large among the 
many things that will never be taken for granted again as 
COVID-19 crises continue. 
     Researchers' biggest concern is that high authorities might 
come to a point to put their gains ahead of volunteers' safety. 
Several ethical concepts are prone to be overlooked. In harsher 
words, today, research bioethics are more likely to be violated 
than ever. This academic article will emphasize the research 
ethics implementation and discuss the major challenges that 
researchers and regulatory bodies might face. Furthermore, it 
explores new ways of reciprocity and collaborations among 
academia, researchers, scientists, and high authorities 
surrounding the role of both local and international research 
ethics boards to authorize future research plans during a 
pandemic in accordance with the ethical principles of respect, 
beneficence, and justice.  
 
Working in a collaborative team   
Today, people worldwide are in one trench facing a common 
threat, and monitoring the pandemic spread in grave concern. 
They look highly on scientists and researchers to guide the ship 
to a safe harbor. It would be preposterous for each research 
center to work independently. Starting a new trial from scratch 
means going through the same issues again exposing new 
volunteers to unnecessary risks. Effective communications 
among scientists to share preliminary trials` results help them 
conduct comparable study designs and characteristics that make 
systematic reviews and meta-analyses, subsequently, easier, and 
juicier. Clinically actionable data must diffuse rapidly crossing 
borders, even when such knowledge does not meet the rigorous 
standards of clinical trials [1,2]. 
 
Expedited reports of a study drug  
Novel interventions to prevent and treat COVID-19 are needed 
all over the world. Likewise, there is a similar need for 
reciprocity. Most of the highly reputable publishing houses 
have made COVID-19 related research articles open to access 
in a bid to create a shared pool of data about the pandemic. 
Sharing the pharmacological data of a drug in a trial is 
invaluable to reduce adverse drug events that could claim lives 
[3]. On top of that, sharing information could change the 
product safety profile and probably helps make more sound 
decisions by the regulators. Such actions could be in the form of 
pausing or terminating an ongoing study. Expedited reports 
should include all severe expected and unexpected; related, and 
unrelated adverse drug reactions (ADRs). Different jurisdictions 
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have different reporting time frames as to routine and expedited 
reporting. 
 
Debriefing at research centers  
Debriefing is an informal experience exchange session designed 
to improve team performance and effectiveness from lessons 
learned and reinforce positive behaviors. It is a high quality-
standard implemented in different industries, where the health 
industry is no exception [4]. At world-class businesses, briefing 
and debriefing are ingrained in the staff`s culture. Sharing 
debriefing minutes on public health domains helps researchers 
avoid taking unnecessary risks of trying a drug if proved 
elsewhere not to be effective. It cannot be overemphasized that 
scientists worldwide are prompted to stay connected to share 
relevant drug and device manufacturing information honestly 
and quickly. 
 
What institutional research boards (IRBs) can do?  
As researchers and participants' safety is concerned, IRB should 
ensure that data collectors must adhere to social distancing rules 
and wear personal protective equipment such as face masks and 
shields, gowns, gloves, and whatever applies at this time. 
Moreover, for observational studies where face-to-face 
interviewing and focus grouping are necessary, they should be 
either adjourned or carried out electronically. Electronic 
communication could be live, in-writing, or videotaped. In 
addition to meeting the safety requirements, many secure online 
platforms provide the privacy and confidentiality researchers 
need. The downside of electronic communication is making de-
identification more complex and data breaches possible as 
participants could be identified even if they subscribed using a 
pseudonym. There are several ways to resolve these issues, such 
as turning off the camera and making phone interviews. Still, 
they mean that the researchers and participants cannot see each 
other during the interview. Submitting research proposals, in-
paper, to IRBs must be banned, as only electronic submissions 
should be permitted. Studied surrounding COVID-19 should 
not wait for their turn to be reviewed by the entire ethical board 
members. Instead, they should be put on a fast-track approval 
process. To qualify for priority review, the application must be 
for a drug that treats a serious condition and, if approved, would 
significantly improve safety or effectiveness; such criteria are 
fully met by the COVID-19 condition [5]. Adhering to the 
expedited review policy, unarguably, saves time that could be 
translated to saving lives. 
 
The disadvantaged communities  
As with other pandemics, COVID-19 has revealed the 
interdependence of a globalized world. We must bear shared 
responsibility for solutions as we collectively confront the 
problem. On a closer look, COVID-19 infection is behaving 
fairly in the sense that it affects poor and rich countries equally. 
Being impartial makes treating the two groups the same from a 
research ethics perspective. That is to say, selecting volunteers 
to participate in a study pertaining to a new vaccine, for 
instance, would require the two parties to be tried on 
unbiasedly. Ethically, when a poor population is tried on 
medicine, they should not be denied a full management course 
if the studied medicine proved effective. Failure in doing so is 
going, once again, through a classic example of a research 
ethics challenge that goes back to 1996 when the first 
antiretroviral drug had revolutionized the treatment of acquired 
immunodeficiency syndrome (AIDS), for sub-Saharan African 
sufferers. Unlike indigent nations, affluent often have the 
capability to conduct the clinical trials as wished for. The 
knowledge clinical trials produce and the innovations that result 
must be disseminated by a commitment to justice in ensuring 
equitable access to resultant guidance [6]. 
 
Judicious utilization of resources  
In areas with limited resources where the stock of standard 
treatment or tests for COVID-19 is short, judicious utilization 
of what is available is a great ethical concern. As COVID-19 
cannot be diagnosed reliably on a symptomatic basis because its 
manifestations mimic the seasonal Flu, the insufficient testing 
kits should be spared for the neediest individuals. Dispensing a 
valuable test kit or medicine at these critical situations should 
be according to a priority list. Critically ill patients with 
suggestive symptoms must top the list, followed by hospitalized 
individuals and health-care workers (HCWs). The latter is 
viewed as soldiers in battling the virus. When HCWs are served 
early, they would be able to go back soon to work and fight the 
virus again to save lives. Among hospitalized patients, those 
who are fighting to live must be prioritized. Screening the 
community for COVID-19 should come down to a complete 
halt when resources are scarce. In areas where poor 
governments require their people to undertake their public 
liability by purchasing the diagnostic test and doing it at home, 
an intricate issue might arise. Nasopharyngeal swabbing is not 
an easy technique that ordinary people could reliably perform at 
home. That would be a huge breakthrough if the healthcare 
system was flooded with false-negative results of COVID-19 
giving a false impression of an infection-free community. Major 
world authorities such as world health organization (WHO) 
usually take the lead in supporting developing nations. 
 
Treating vulnerable groups  
Minorities, prisoners, and illegal immigrants should not be 
discriminated against in peace, not to mention in crises such as 
natural disasters and epidemics [7]. In more specific terms, 
vulnerable populations must not be obliged to partake in 
experiments against their will. It is essential to ensure that 
participants are aware of their unconditional right to withdraw 
at any time during the study and the potential risks in taking 
part in given research, including the risk of an online session 
being overheard on either end of devices. It is unfair to select 
vulnerable individuals to be enrolled in a study sparing the rest 
of the population. In doing so, the study results would carry 
many specifications to the minority worked upon, and, 
therefore, it will not be reliably generalizable – ruining the 
external validity of the research. Participants, whatever minority 
they belong to, should not be denied health services related to 
COVID-19 as public health is the major concern at this point. 
Jurisdictions should not deport infected illegal immigrants 
before treating them. Looking at the picture at large, deporting 
poor infected individuals will help spread the disease elsewhere 
on the planet. Besides, the infection would cross back to where 
it came from, probably, in a severer form. 
  
                                                     Katib AA, Journal of Ideas in Health (2020); 3(Special 1):185-187                                                          187  
 
The "human challenge trials"  
Producing a timely, reliable Covid-19 test that can be deployed 
among the population would be a concrete step to flatten the 
curve and limit the pandemic's impact. But even once an 
effective solution could be discovered and deployed on the 
ground, this comes with its own set of ethical issues. 
Practically, infecting volunteers with the virus or part of it could 
accelerate developing a vaccine; but raises tough ethical 
questions. The ethical challenge is that; is it acceptable to 
deliberately infect healthy people with a disease that could kill 
them, and for which there is no cure? An ethical question that 
demands answers [8,9]. The United States Food and Drug 
Administration (FDA) has offered to work with those interested 
in conducting human challenge trials to evaluate these issues. 
The WHO has issued a paper outlining the key criteria for 
Covid-19 human challenge studies' ethical acceptability. 
Among these, the initial studies should be limited to healthy 
young adults aging 18 to 30 yrs., in whom fatal infection rates 
are estimated at 0.03%. In an attempt to minimize the potential 
biohazard on participants, health workers, and research sites, 
The NIH group suggests developing a special “challenge strain” 
with reduced virulence to administer in challenge trials. 
 
Conclusion  
The research community must work as one team across 
continents. They are required to be flexible at research 
methodologies, yet rigid in implementing research ethics in the 
time of COVID-19 pandemic and beyond. 
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